|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2900 Ames Crossing Road |
Address2 |
|
City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
|
5. Senate ID# 400339576-12
|
||||||||
|
6. House ID# 403630000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: David Root |
Date | 1/18/2024 4:03:47 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S 1339, Pharmacy Benefit Manager Reform Act-provisions related to disclosure, audits and PBM contracting. H.R. 3682 of the 117th Congress Improving Transparency to Lower Drugs Costs Act of 2021-provisions related to public disclosure of drug rebate and other data. Transparency in Coverage Final Rule (CMS-9915-F) provisions related to machine readable drug files. S. 3548 A bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R. 5378 Lower Costs, More Transparency Act provisions related to PBM transparency and disclosure requirements. S. 1542/H.R. 6283 The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S. 3430, Better Mental Healthcare, Lower Cost Drugs & Extenders Act-provisions related to PBMs and pharmacy contracting. S. 2973 Modernizing and Ensuring PBM Accountability Act -provisions related to PBM contracting, audits and disclosures. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. H.R. 5461 Ensuring Access to Lower Cost Medicines for Seniors Act of 2023-provisions related to cost-sharing for generics and biosimilars in Medicare Part D. S. 2436 Neighborhood Options for Patients Buying Medicines (NO PBMs) Act-provisions related to pharmacy contracting under Medicare. H.R. 2880 Protecting Patients Against PBM Abuses Act-provisions regulating PBM reimbursement in Part D contracts. H.R. 5386 Cutting Copays Act provisions relating to changes to co-pays for Medicare Part D low-income beneficiaries. H.R. 4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program. H.R. 5372 Expanding Seniors Access to Lower Cost Medicines Act of 2023-to amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars. H.R. 5393 The Transparency and Fairness for Pharmacists Act-provisions relating to pharmacy assessment in Medicare Part D. H.R. 5385 Medicare PBM Accountability Act; to amend Title XVIII of the Social Security Act to establish pharmacy benefit manager reporting requirements with respect to prescription drug plans and MA-PD plans under Medicare Part D. H.R. 1352, Increasing Access to Biosimilars Act of 2023-provisions related to a demonstration project providing additional provider payments for providers of biosimilars. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |